Eylea

Outcomes differ from trials with ‘real-world’ anti-VEGF therapy for DMEThe visual outcomes after anti-VEGF therapy administered to treat diabetic macular edema in the “real world” do not achieve those reported in randomized clinical trials. Eyes with better baseline visual acuity are disproportionately affected.
Using OCT with your diabetes patientsOCT is one of the best way to assess patients for the presence of diabetic macular edema (DME)
Anti-VEGF drugs: Safe and effective for treating DMEData from large randomized trials indicate that diabetic macular edema can be treated safely and effectively with anti-vascular endothelial growth factor therapies.
Rescue alfibercept treatment proves successful for patients with BRVOPatients with branch retinal vein occlusion had better visual outcomes and decreased macular edema following intravitreal injection of aflibercept compared with laser treatment.
FDA expanded approval of aflibercept injection to treat diabetic retinopathyFDA has expanded the approval of aflibercept (Eylea, Regeneron) injection to treat diabetic retinopathy in patients with macular edema.
FDA drug approvals-March 2015FDA actions in brief, breakthrough designation, recommended for approval, priority review, fast-track designations
Eylea far better for DME patients, NIH study reports
Eylea far better for DME patients, NIH study reportsAflibercept is reportedly superior to ranibizumab and bevacizumab when treating some patients with diabetic macular edema (DME), according to a National Institutes of Health (NIH)-sponsored clinical trial.
AMD treatment market to exceed $10 billion by 2023According to a report from GlobalData, the age-related macular degeneration treatment market in the U.S., UK, Germany, France, Spain, Italy, and Japan will double in value from $5.1 billion in 2013 to $10.1 billion in 2023.
FDA grants priority review to aflibercept for diabetic retinopathy in patients with DMEThe FDA has accepted for priority review Regeneron Pharmaceuticals’ supplemental biologics license application for aflibercept (Eylea) injection, a treatment of diabetic retinopathy in patients with diabetic macular edema (DME).
Health Canada approves Eyelea for DME treatmentHealth Canada recently approved Eylea (aflibercept, Regeneron) for the treatment of diabetic macular edema (DME).